CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 116 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $118,308 | -94.9% | 4,299 | -93.8% | 0.00% | -100.0% |
| Q2 2023 | $2,335,979 | +4.8% | 68,847 | +11.1% | 0.01% | -20.0% |
| Q1 2023 | $2,228,781 | +48.5% | 61,945 | +84.0% | 0.01% | +25.0% |
| Q4 2022 | $1,500,850 | +614.7% | 33,674 | +350.4% | 0.01% | +700.0% |
| Q3 2022 | $210,000 | -84.3% | 7,476 | -88.5% | 0.00% | -95.2% |
| Q1 2021 | $1,337,000 | -55.4% | 64,913 | -62.1% | 0.02% | -51.2% |
| Q4 2020 | $3,001,000 | +175.1% | 171,318 | +132.8% | 0.04% | +168.8% |
| Q3 2020 | $1,091,000 | +131.1% | 73,584 | +102.5% | 0.02% | +128.6% |
| Q2 2020 | $472,000 | – | 36,334 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |